Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TYMS | P04818 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.35 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | TDP2 | O95551 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL436140 | 0.79 | HTR5A (0.44) | MAOAMAOBKDM4EALDH1A1TYMS | |
| SCHEMBL3605242 | 0.79 | MAOA (0.37) | MAOAMAOBKDM4EALDH1A1TYMS | |
| SCHEMBL14805480 | 0.79 | ALDH1A1 (0.39) | MAOAMAOBKDM4EALDH1A1TYMS | |
| SCHEMBL3604854 | 0.73 | CYP11B1 (0.36) | ALDH1A1CYP11B1CYP11B2 | |
| SCHEMBL3599771 | 0.71 | NR3C2 (0.47) | ALDH1A1CYP11B1CYP11B2AHR | |
| SCHEMBL3593737 | 0.70 | NPC1 (0.50) | KDM4ECYP1A2CYP11B1CYP11B2AHR | |
| SCHEMBL464780 | 0.69 | AHR (0.50) | MAOAMAOBKDM4EALDH1A1TYMS | |
| SCHEMBL3639275 | 0.69 | CA12 (0.37) | CYP11B1CYP11B2AHR | |
| Hydrochloric Acid SCHEMBL10918416 | 0.68 | AHR (0.48) | MAOAMAOBKDM4EALDH1A1TYMS | |
| SCHEMBL3593391 | 0.67 | RXFP1 (0.36) | KDM4EALDH1A1AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128157-A1 | HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | CCNY, CCND3, NSD3 | MAOA 1461/4885MAOB 1349/4885KDM4E 2284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.